Log in

NASDAQ:COLLCollegium Pharmaceutical Stock Price, Forecast & News

$18.92
+0.03 (+0.16 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$18.72
Now: $18.92
$19.58
50-Day Range
$15.78
MA: $17.19
$18.92
52-Week Range
$10.41
Now: $18.92
$25.59
Volume426,700 shs
Average Volume554,702 shs
Market Capitalization$653.23 million
P/E RatioN/A
Dividend YieldN/A
Beta0.97
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting. The company offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. Furhter, it offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Read More
Collegium Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:COLL
CUSIPN/A
Phone781-713-3699

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$296.70 million
Book Value$2.61 per share

Profitability

Net Income$-22,720,000.00

Miscellaneous

Employees266
Market Cap$653.23 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$18.92
+0.03 (+0.16 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive COLL News and Ratings via Email

Sign-up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions

How has Collegium Pharmaceutical's stock been impacted by Coronavirus (COVID-19)?

Collegium Pharmaceutical's stock was trading at $17.57 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, COLL shares have increased by 7.7% and is now trading at $18.92.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Collegium Pharmaceutical?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Collegium Pharmaceutical
.

When is Collegium Pharmaceutical's next earnings date?

Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Collegium Pharmaceutical
.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical Inc (NASDAQ:COLL) released its earnings results on Wednesday, August, 5th. The specialty pharmaceutical company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.24 by $0.01. Collegium Pharmaceutical had a return on equity of 0.17% and a net margin of 0.07%.
View Collegium Pharmaceutical's earnings history
.

What price target have analysts set for COLL?

9 brokerages have issued 12 month price targets for Collegium Pharmaceutical's shares. Their forecasts range from $8.00 to $43.00. On average, they anticipate Collegium Pharmaceutical's stock price to reach $28.71 in the next year. This suggests a possible upside of 51.8% from the stock's current price.
View analysts' price targets for Collegium Pharmaceutical
.

Has Collegium Pharmaceutical been receiving favorable news coverage?

Media headlines about COLL stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Collegium Pharmaceutical earned a daily sentiment score of -4.1 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.
View the latest news about Collegium Pharmaceutical
.

Are investors shorting Collegium Pharmaceutical?

Collegium Pharmaceutical saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 4,390,000 shares, an increase of 82.2% from the January 31st total of 2,410,000 shares. Based on an average trading volume of 587,500 shares, the days-to-cover ratio is currently 7.5 days. Approximately 14.5% of the company's shares are sold short.
View Collegium Pharmaceutical's Short Interest
.

Who are some of Collegium Pharmaceutical's key competitors?

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Canopy Growth (CGC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Bausch Health Companies (BHC) and Intercept Pharmaceuticals (ICPT).

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the following people:
  • Mr. Michael Thomas Heffernan, Co-Founder & Chairman (Age 55)
  • Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 48)
  • Mr. Paul J. Brannelly, Exec. VP & CFO (Age 46)
  • Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 44)
  • Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel & Sec. (Age 35)

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Emerald Advisers LLC (1.68%), Emerald Mutual Fund Advisers Trust (1.53%), Mesirow Financial Investment Management Equity Management (0.86%), Bank of Montreal Can (0.69%), Bank of New York Mellon Corp (0.54%) and WINTON GROUP Ltd (0.52%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan and Scott Dreyer.
View institutional ownership trends for Collegium Pharmaceutical
.

Which major investors are selling Collegium Pharmaceutical stock?

COLL stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Goldman Sachs Group Inc., Smith Asset Management Group LP, ClariVest Asset Management LLC, Fisher Asset Management LLC, Dupont Capital Management Corp, and Mesirow Financial Investment Management Equity Management. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, and Scott Dreyer.
View insider buying and selling activity for Collegium Pharmaceutical
.

Which major investors are buying Collegium Pharmaceutical stock?

COLL stock was acquired by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Cadence Capital Management LLC, WINTON GROUP Ltd, Chartwell Investment Partners LLC, 1492 Capital Management LLC, Knott David M, Monarch Partners Asset Management LLC, and Swiss National Bank.
View insider buying and selling activity for Collegium Pharmaceutical
.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $18.92.

How big of a company is Collegium Pharmaceutical?

Collegium Pharmaceutical has a market capitalization of $653.23 million and generates $296.70 million in revenue each year. The specialty pharmaceutical company earns $-22,720,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.

What is Collegium Pharmaceutical's official website?

The official website for Collegium Pharmaceutical is www.collegiumpharma.com.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.